See the DrugPatentWatch profile for Vuity
Vuity (pilocarpine hydrochloride ophthalmic solution) has not yet received approval from the European Medicines Agency (EMA). It is currently approved in the United States by the Food and Drug Administration (FDA) for the treatment of presbyopia [1].
What is Vuity and how does it work?
Vuity is a prescription eye drop that works by temporarily narrowing the pupil, which enhances the eye's ability to focus on near objects [1]. This effect is achieved through the cholinergic agonist properties of pilocarpine, which stimulates the muscles in the iris and ciliary body [1].
When did Vuity get FDA approval?
Vuity received FDA approval on October 21, 2021 [1].
What are the side effects of Vuity?
Common side effects of Vuity include headache and eye redness. Other reported side effects can include blurred vision, eye strain, and diminished night vision [1].
Are there alternatives to Vuity for presbyopia?
While Vuity is a pharmacological option, other approaches to managing presbyopia exist. These include reading glasses, multifocal contact lenses, and surgical options such as refractive lens exchange or corneal inlays [2].
How does pilocarpine work in treating presbyopia?
Pilocarpine is a muscarinic receptor agonist. When applied to the eye, it causes contraction of the iris sphincter muscle, leading to pupillary miosis (pupil constriction). This pupillary constriction increases the depth of field of the eye, effectively improving near vision for individuals with presbyopia. The effect is temporary, lasting for a portion of the day [1].
When does Vuity's patent expire?
Information regarding the specific patent expiry for Vuity is not readily available, but patent information for pharmaceuticals can be tracked through resources like DrugPatentWatch.com [3].
Sources:
1. https://www.vuity.com/
2. https://www.aao.org/eye-health/diseases/presbyopia
3. https://drugpatentwatch.com/